Genetic and epigenetic characterization of sarcoma stem cells across subtypes identifies EZH2 as a therapeutic target
Abstract High-grade soft tissue sarcomas (STS) are a heterogeneous and aggressive set of cancers. Failure to respond anthracycline chemotherapy, standard first-line treatment, is associated with poor outcomes. We investigated the contribution of STS cancer stem cells (STS-CSCs) to doxorubicin resist...
Saved in:
Main Authors: | Edmond O’Donnell, Maria Muñoz, Ryan Davis, Jessica Bergonio, R. Lor Randall, Clifford Tepper, Janai Carr-Ascher |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Precision Oncology |
Online Access: | https://doi.org/10.1038/s41698-024-00776-7 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Targeting EZH1/2: tackling epigenetic resistance advances cancer therapy
by: Ram Abou Zaki, et al.
Published: (2025-01-01) -
Transcriptomic and proteomic profiling identifies feline fibrosarcoma as clinically amenable model for aggressive sarcoma subtypes
by: Mikiyo Weber, et al.
Published: (2025-02-01) -
YPEL2 regulates the efficacy of BRD4-EZH2 dual targeting in EZH2Y641mut germinal center-derived lymphoma
by: Aránzazu Chamorro-Jorganes, et al.
Published: (2025-03-01) -
The sarcoma ring trial: a case-based analysis of inter-center agreement across 21 German-speaking sarcoma centers
by: Siyer Roohani, et al.
Published: (2025-01-01) -
Human soft tissue sarcomas harbor an intratumoral viral microbiome which is linked with natural killer cell infiltrate and prognosis
by: William J Murphy, et al.
Published: (2023-01-01)